An allogeneic CD19 CAR‐T (“TyU19”) is currently evaluated in IIM and systemic sclerosis, showing sustained peripheral B‐cell aplasia and a favorable safety profile at 6 months (NCT06462144). This evidence concerns the gene CD19 and systemic sclerosis.